A novel non-invasive technique for pediatric phimosis treatment: assessing efficacy and post-treatment family care — a retrospective cohort study Authors: Xia Zhao, Li Zhang, Nan Jin Published: 2026 ABSTRACT AbstractBackgroundThe European Association of Urology 2024–2025 guidelines recommend conservative management as first-line therapy for pediatric phimosis before considering surgical intervention. Balloon catheter dilation treatment (BCDT) has emerged as a promising foreskin-preserving approach, yet high-quality comparative evidence against conventional circumcision (CC) remains limited. This study aimed to compare the clinical efficacy, safety outcomes, and family-centered measures between BCDT and CC in a pediatric cohort.MethodsThis retrospective cohort study enrolled 200 boys (aged 2–12 years) with Kikiros grade ≥ 2 phimosis treated between January and December 2024 at a tertiary pediatric surgery center. Patients were allocated to BCDT (n = 100) or CC (n = 100) groups based on treatment received. Primary outcomes included cure rates (Kikiros grade 0–1) at 6 months. Secondary outcomes encompassed procedure-related parameters, complication rates, pain assessment using the Face, Legs, Activity, Cry, Consolability (FLACC) scale, healing time, parent-reported satisfaction, and health literacy-associated compliance measures. Propensity score analysis confirmed baseline comparability. Number needed to treat (NNT) and effect sizes (Cohen’s d) were calculated to quantify clinical significance.ResultsBoth treatments achieved high 6-month cure rates (BCDT: 98.0% vs. CC: 100.0%; P = 0.497; absolute risk difference: 2.0%, 95% CI: -0.7% to 4.7%). BCDT demonstrated substantial advantages in procedure efficiency (mean operative time: 5.03 ± 0.62 vs. 29.38 ± 6.69 min; P < 0.001; Cohen’s d=-5.13) and recovery parameters (healing time: 6.74 ± 2.13 vs. 15.90 ± 3.06 days; P < 0.001; Cohen’s d=-3.47). Pain-related outcomes significantly favored BCDT: lower incidence (65.0% vs. 99.0%; P < 0.001; NNT = 3), shorter duration (21.2 ± 14.0 vs. 93.2 ± 55.6 h; P < 0.001), and reduced FLACC scores at 24 h (2.59 ± 1.44 vs. 5.22 ± 2.07; P < 0.001; Cohen’s d=-1.48). Edema occurrence was substantially lower in the BCDT group (60.0% vs. 100.0%; P < 0.001; NNT = 2.5). Parent satisfaction rates (score 5, very satisfied) were 96.0% and 88.0% for BCDT and CC, respectively (P = 0.068). Parent health literacy (Newest Vital Sign score) positively correlated with home care compliance (r = 0.42; P < 0.001), with adequate literacy (NVS ≥ 4) associated with significantly better adherence (3.21 ± 0.58 vs. 2.74 ± 0.71; P < 0.001).ConclusionsIn this retrospective cohort, BCDT achieved short-term (6-month) cure rates non-inferior to CC while offering clinically meaningful advantages in procedural simplicity (6-fold reduction in operative time), pain mitigation (34% absolute reduction in incidence), accelerated healing (2.4-fold faster), and enhanced parent satisfaction. As a foreskin-preserving, minimally invasive option requiring only topical anaesthesia, BCDT may be considered for carefully selected symptomatic children with pathological phimosis, within a stepwise conservative management strategy that includes watchful waiting and topical corticosteroids as first-line therapy. Routine intervention for asymptomatic physiological phimosis is not supported by these data, and durable cure, long-term recurrence prevention, and broad first-line adoption require confirmation in prospectively designed studies with follow-up extending beyond puberty. Outcomes are optimised when supported by adequate parent health literacy for post-procedure home-care adherence.Keywords: Phimosis, Balloon catheter dilation, Circumcision, Pediatric urology, Minimally invasive treatment, Foreskin preservation, Patient-reported outcomes, Health literacy Introduction Phimosis, characterized by the inability to retract the prepuce over the glans penis, is one of the most frequent urological conditions encountered in paediatric practice. The European Association of Urology (EAU) 2024–2025 Paediatric Urology Guidelines report an incidence of 9–20% among boys aged 5–13 years, decreasing to approximately 1% by 16–18 years [1]. The distinction between physiological phimosis—a developmental phenomenon that typically resolves spontaneously by puberty and does not require intervention in the absence of symptoms—and pathological phimosis (driven by scarring, BXO, recurrent balanoposthitis, or voiding dysfunction) remains a cornerstone of appropriate management [2]. The present study, and the indications described below, concern symptomatic / pathological phimosis only; asymptomatic physiological phimosis was not an indication for intervention at our centre. Contemporary guidelines have increasingly emphasized conservative approaches as first-line therapy for pediatric phimosis. The 2024 Cochrane systematic review by Moreno et al., analyzing 12 randomized controlled trials with 1,395 participants, demonstrated that topical corticosteroids significantly improve complete phimosis resolution compared with placebo (risk ratio 2.45, 95% CI 1.84–3.27; number needed to treat = 5) [3]. A subsequent network meta-analysis by Shanmugham et al. (2025) further established that low-to-moderate potency corticosteroids achieve comparable efficacy to high-potency formulations, supporting a conservative pharmacological approach [4]. In parallel, a 2024 randomized double-blind trial by Nunes e Santos et al. evaluated whether the addition of hyaluronidase to betamethasone enhances topical-treatment efficacy in paediatric phimosis, illustrating ongoing refinement of conservative pharmacological strategies [5]. Despite this evidence favoring medical management, a 2025 paradigm-shift analysis by Fuentes et al. revealed that 47% of phimosis surgeries in their cohort involved asymptomatic physiological cases—suggesting persistent overutilization of surgical intervention [2]. Conventional circumcision (CC) remains the most commonly performed surgical procedure for phimosis worldwide. The comprehensive meta-analysis by Shabanzadeh et al. (2021), encompassing 351 studies and over 4 million participants, quantified overall complication rates at 3.84% (95% CI 3.35–4.37%), with therapeutic circumcisions demonstrating a 2-fold increase compared with elective procedures (7.47% vs. 3.34%) [6]. More recent evidence from Zhang et al. (2024) comparing circumcision techniques in 1,260 pediatric patients reported procedure times averaging 28–35 min with healing periods of 14–21 days [7]. The 2024 systematic review by Yao et al. further confirmed that circumcision, while effective, carries inherent risks of bleeding, infection, and prolonged recovery that may be avoided with less invasive alternatives [8]. Balloon catheter dilation treatment (BCDT) has emerged as a foreskin-preserving approach that mechanically dilates the phimotic ring through controlled balloon expansion. The technique was originally described by He and Zhou in 1991 in a single-centre series of 512 paediatric cases reported in the Chinese Medical Journal, [9] and has since been adopted in Chinese paediatric urology practice, with concurrent clinical and nursing-care reports documenting its routine delivery in inpatient settings [10]. Recent narrative reviews of prepuce-preserving management for urologists have similarly highlighted the broadening menu of non-excisional therapeutic options for phimosis alongside the persistent gap between technique availability and high-quality comparative evidence [11]. However, high-quality peer-reviewed international comparative data evaluating BCDT against conventional circumcision under contemporary methodological standards — including validated paediatric pain instruments (such as the FLACC scale), propensity-score-based balance diagnostics, and effect-size quantification — remain limited, which is a primary motivation for the present study. Despite these promising findings, several critical evidence gaps remain. First, comprehensive comparative assessments incorporating validated pain instruments (such as the FLACC scale for pediatric populations) are lacking. Second, the influence of family-centered factors—particularly parent health literacy and its relationship to home care compliance—has not been systematically evaluated. The Newest Vital Sign (NVS) instrument, validated across diverse pediatric populations, offers a rapid and reliable assessment of health literacy that may inform patient selection and educational strategies [12]. Third, effect size quantification and number-needed-to-treat calculations are essential for translating statistical significance into clinical decision-making. This study aimed to address these knowledge gaps through a retrospective comparison of BCDT versus CC in symptomatic paediatric phimosis, incorporating: (1) validated outcome instruments for pain and quality-of-life assessment; (2) effect-size calculations to quantify clinical meaningfulness; and (3) novel evaluation of parent health literacy as a determinant of treatment adherence. We hypothesised that, in this selected symptomatic cohort, BCDT would demonstrate non-inferior short-term (6-month) anatomical efficacy with superior safety and recovery parameters compared with CC. The study was not designed to compare interventional treatment against watchful waiting or topical corticosteroid therapy, both of which remain first-line options for physiological phimosis under current guidelines. Materials and methods Study design and ethical considerations This was a single-centre, retrospective, non-randomised cohort study; it was not a prospectively registered controlled trial. The study protocol was approved by the Institutional Review Board and conducted in accordance with the Declaration of Helsinki. Given the retrospective design utilising de-identified medical records, the requirement for individual informed consent was waived. This manuscript was prepared following the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines [13]. Participants and eligibility criteria We systematically reviewed medical records of all patients treated for phimosis between 1 January 2024 and 31 December 2024. Inclusion criteria were: (1) male patients aged 2–12 years; (2) clinical diagnosis of phimosis with Kikiros grade ≥ 2; (3) a documented clinical indication for intervention — i.e., symptomatic / pathological phimosis as defined by ≥ 1 of the following: recurrent balanitis or balanoposthitis (≥ 2 episodes in the preceding 12 months), urinary symptoms attributable to phimosis (dysuria, weak/deflected stream, post-void dribbling), preputial ballooning during voiding, visible scarring or cicatricial ring, clinically suspected (non-confirmed) BXO under surveillance, recurrent urinary tract infection, persistent symptomatic phimosis after ≥ 4 weeks of topical corticosteroid therapy where attempted, or persistent symptomatic phimosis with documented parental concern after counselling on watchful waiting; (4) treatment with either BCDT or CC during the study period; (5) availability of complete baseline assessment and ≥ 6-month follow-up; and (6) parent/guardian participation in outcome assessments [14]. Asymptomatic physiological phimosis was not an indication for either intervention at our centre during the study period. Exclusion criteria included: (1) histopathologically confirmed BXO, which represents a distinct pathological entity with different treatment algorithms; [15] (2) previous surgical or interventional treatment for phimosis; (3) concomitant urogenital anomalies (hypospadias, buried penis, megaprepuce); (4) coagulopathy or immunodeficiency; (5) incomplete follow-up data (missing > 20% of scheduled visits); (6) parental inability to complete assessment instruments due to language barriers; and (7) asymptomatic physiological phimosis without any of the indications listed above. Intervention protocols Balloon Catheter Dilation Treatment (BCDT): All procedures were performed by paediatric surgeons with ≥ 3 years of experience in the technique, following a standardised institutional protocol. Topical anaesthesia was achieved with 1% lidocaine cream (EMLA equivalent) applied to the preputial orifice for 5 min. A sterile medical-grade balloon catheter (Suzhou Shengda Medical Devices Co., Ltd., China; diameter range 4–8 mm based on patient anatomy) was gently introduced into the preputial space. Where congenital preputial adhesions were present, they were lysed by blunt separation under direct vision during the same procedure, immediately before balloon inflation; no sharp dissection was used. The balloon was then incrementally inflated with 2–5 mL of air to achieve controlled circumferential dilation of the phimotic ring, targeting expansion to 3–5 mm beyond the coronal sulcus diameter. Each inflation was maintained for 20–30 s and repeated 2–3 times per session. Post-procedure care included immediate application of erythromycin ophthalmic ointment and written + verbal home-care instructions. Foreskin retraction (stretching) exercises were deliberately deferred to postoperative day 14 (rather than initiated immediately) to allow (i) resolution of procedure-related preputial oedema, which peaks in the first 72–96 h and resolves by approximately day 10–14; (ii) re-epithelialisation of any minor mucosal abrasions caused by balloon dilation or by blunt adhesiolysis; (iii) minimisation of procedure-site pain that could provoke withdrawal-and-reflex tightening during early stretching and so paradoxically promote re-stenosis; and (iv) consolidation of the dilated preputial ring before applying ongoing mechanical stress, balancing the competing risks of premature re-stenosis (if stretch is delayed too long) and stretch-induced micro-tears or pain-avoidance non-adherence (if stretch is begun too early). Stretching was then performed twice daily for 10 min during bathing. Topical corticosteroids were not administered as pretreatment before BCDT (or before CC) at our centre during the study period; the implications of this practice pattern are addressed in the Limitations section. Conventional Circumcision (CC): Standard sleeve-resection technique was performed under general anaesthesia (patients < 6 years) or caudal epidural block (patients ≥ 6 years) based on established anaesthetic protocols [16]. Any preputial adhesions were taken down bluntly at the time of foreskin retraction prior to incision. The procedure involved circumferential incision, controlled foreskin excision with frenulum preservation when anatomically feasible, meticulous haemostasis using bipolar electrocautery, and mucocutaneous approximation with 5 − 0 absorbable sutures (Vicryl Rapide). As with the BCDT group, no patient in the CC group received topical corticosteroid pretreatment. Post-operative management included non-adherent wound dressings, twice-daily antiseptic cleansing with povidone-iodine solution, oral analgesics as needed, and activity restriction for 14 days. Outcome measures The primary outcome was treatment success (cure) at 6 months, defined as achievement of Kikiros grade 0–1 (complete foreskin retractability with smooth exposure of the coronal sulcus and glans, without residual phimotic ring or scarring) [17]. Secondary efficacy outcomes included cure rate at 4 weeks and categorical improvement in Kikiros grade from baseline. Safety outcomes encompassed a comprehensive complication profile: (1) pain occurrence and duration, assessed using the Face, Legs, Activity, Cry, Consolability (FLACC) scale at 24 h post-procedure (validated for children aged 2 months to 7 years [18]; score 0–10, with ≥ 4 indicating significant pain requiring intervention); (2) edema occurrence and duration; (3) bleeding requiring intervention; (4) dysuria; (5) local infection; (6) wound dehiscence (CC group); (7) incarceration/paraphimosis (both groups); and (8) time to complete healing (defined as epithelialization without crusting or discharge). Procedural outcomes included operative time (from anesthesia completion to dressing application) and anesthesia type. Patient-reported outcomes comprised: (1) parent satisfaction measured on a 5-point Likert scale (1 = very dissatisfied to 5 = very satisfied) at 6 months; (2) Net Promoter Score (NPS; 0–10 scale) to assess recommendation likelihood; and (3) Pediatric Quality of Life Inventory (PedsQL 4.0) generic core scales at baseline and 6 months [19]. Family-centered outcomes included: (1) parent health literacy assessed using the Newest Vital Sign (NVS) instrument, a 6-item validated measure administered in approximately 3 min (score 0–6; ≥4 indicates adequate health literacy) [20]; (2) State-Trait Anxiety Inventory (STAI) scores at baseline and 6 months; and (3) home care compliance assessed using a modified 4-item Morisky-derived Medication Adherence Scale adapted for wound care and exercise protocols (score 0–4; higher scores indicate better adherence) [21]. Statistical analysis Sample size was determined a priori based on the primary outcome. Assuming a 6-month cure rate of approximately 95% for BCDT — a conservative estimate informed by early single-centre paediatric BCDT case series in the Chinese-language literature, including the foundational He and Zhou 1991 report [9] — and 100% for CC, with α = 0.05 (one-sided) and 80% power for a non-inferiority margin of 10%, approximately 95 patients per group were required. We enrolled 100 patients per group to account for attrition. The 10% non-inferiority margin was selected a priori on clinical grounds: (i) CC, by virtue of complete foreskin removal, achieves an anatomical cure rate close to 100%, so any conservative alternative is mathematically capped in absolute terms; (ii) a ≤ 10% absolute reduction in 6-month anatomical cure was judged by our paediatric urology team to be the largest difference that families would be willing to accept in exchange for avoiding general anaesthesia, the larger wound, the longer healing time, and the irreversible loss of foreskin tissue; and (iii) this margin is consistent with the range of cure-rate differences reported across heterogeneous BCDT case series in the Chinese-language literature. Non-inferiority was evaluated using the two-sided 95% confidence interval for the absolute risk difference (BCDT minus CC); non-inferiority was concluded if the lower bound of the 95% CI lay above − 10%. Continuous variables were assessed for normality using Shapiro-Wilk tests and presented as mean ± standard deviation (SD) or median (interquartile range [IQR]) as appropriate. Categorical variables were expressed as frequencies and percentages. Between-group comparisons utilized independent-samples t-tests or Mann-Whitney U tests for continuous variables and chi-square or Fisher’s exact tests for categorical variables. To assess (rather than adjust for) potential selection bias, propensity score analysis was performed for balance diagnostics only; propensity scores were NOT used for matching, inverse-probability weighting, or covariate-adjusted outcome regression. Propensity scores were estimated using logistic regression incorporating the following covariates: age, weight, baseline Kikiros grade, disease duration, history of balanitis, NVS health-literacy score, and baseline STAI score. Standardised mean differences (SMD) were calculated, with SMD < 0.1 indicating adequate balance between groups [22]. Because all SMDs were below 0.1, no further propensity-score-based adjustment of effect estimates was performed; reported between-group comparisons therefore reflect unadjusted differences in this balanced cohort. Effect sizes were calculated using Cohen’s d for continuous outcomes, interpreted as small (0.2), medium (0.5), or large (≥ 0.8) [23]. For binary outcomes, odds ratios (OR) with 95% confidence intervals (CI) were calculated, along with absolute risk differences and number needed to treat (NNT) to quantify clinical significance. Correlation between health literacy and compliance was assessed using Pearson’s correlation coefficient. All analyses were performed using Python 3.12 (scipy 1.11, statsmodels 0.14) and R version 4.3.2 (MatchIt and cobalt packages for propensity score analysis). A two-sided P-value < 0.05 was considered statistically significant. Missing data (< 5% for all variables) were handled using complete-case analysis after confirming the missing-completely-at-random assumption. Results Study population and baseline characteristics During the study period, 247 patients were screened for eligibility. After excluding 23 patients with histopathologically confirmed BXO, 11 with prior interventions, 8 with concurrent urogenital anomalies, and 5 with incomplete follow-up, 200 patients (100 in each group) were included in the final analysis (Fig. 1). Follow-up completion was 196/200 (98.0%) at 4 weeks (BCDT 98/100, CC 98/100) and 184/200 (92.0%) at 6 months (BCDT 92/100, CC 92/100); cure-rate denominators reported below therefore refer to the number of patients with assessable outcome data at each time point. There was no significant differential attrition between groups (χ², P = 1.000). Treatment efficacy and procedural outcomes. A Kikiros grade progression in the BCDT group demonstrating improvement from baseline (median 4) through 4 weeks (median 2) to 6 months (median 0). Box plots show median, interquartile range, and range; the red line indicates mean trajectory. B Comparison of procedure time (left panel) and healing time (right panel) between groups. Violin plots display distribution density; internal box plots show median and interquartile range. Effect sizes (Cohen’s d) are indicated. C FLACC pain scores at 24 h post-procedure. Dashed line indicates clinical threshold for significant pain (score ≥ 4). D Complication rates comparison showing pain, edema, bleeding, dysuria, and infection incidence by treatment group. Error bars represent 95% confidence intervals. BCDT, balloon catheter dilation treatment; CC, conventional circumcision. ***P < 0.001; ns, not significant Baseline demographic and clinical characteristics are presented in Table 1. The two groups were well-balanced across all measured covariates. Mean age was 5.58 ± 2.61 years (BCDT) versus 5.64 ± 2.71 years (CC) (P = 0.855). Baseline phimosis severity was comparable, with median Kikiros grade of 4 (IQR 4–5) in both groups (P = 0.506). Disease duration, anthropometric measures, previous balanitis history, and baseline health-related measures showed no statistically significant differences (all P > 0.05). Propensity score analysis confirmed adequate balance with all SMD values below the 0.1 threshold, indicating minimal residual confounding. Table 1Baseline Demographic and Clinical Characteristics of Study ParticipantsCharacteristicBCDT (n = 100)CC (n = 100)P-valueSMDAge, years, mean ± SD5.58 ± 2.615.64 ± 2.710.8550.02Weight, kg, mean ± SD19.95 ± 6.8420.45 ± 7.150.6150.07Height, cm, mean ± SD109.35 ± 16.83109.90 ± 17.140.8200.03BMI, kg/m², mean ± SD16.24 ± 2.0616.51 ± 1.970.3420.13Kikiros grade, median (IQR)4 (4–5)4 (4–5)0.5060.09Grade 2, n (%)8 (8.0)10 (10.0)--Grade 3, n (%)15 (15.0)12 (12.0)--Grade 4, n (%)52 (52.0)55 (55.0)--Grade 5, n (%)25 (25.0)23 (23.0)--Disease duration, months, mean ± SD17.11 ± 9.8620.02 ± 12.890.0750.25Previous balanitis, n (%)53 (53.0)50 (50.0)0.7770.06NVS health literacy score, mean ± SD4.39 ± 1.384.12 ± 1.530.1930.19STAI anxiety score, mean ± SD41.12 ± 11.8942.39 ± 11.980.4530.11PedsQL baseline score, mean ± SD78.85 ± 10.3176.98 ± 11.740.2320.17Abbreviations: BCDT Balloon catheter dilation treatment, CC Conventional circumcision, SD Standard deviation, BMI Body mass index, IQR Interquartile range, NVS Newest Vital Sign, STAI State-Trait Anxiety Inventory, PedsQL Pediatric Quality of Life Inventory, SMD Standardized mean difference Baseline Demographic and Clinical Characteristics of Study Participants Abbreviations: BCDT Balloon catheter dilation treatment, CC Conventional circumcision, SD Standard deviation, BMI Body mass index, IQR Interquartile range, NVS Newest Vital Sign, STAI State-Trait Anxiety Inventory, PedsQL Pediatric Quality of Life Inventory, SMD Standardized mean difference Primary efficacy outcomes Treatment success rates are summarised in Table 2. At the 4-week assessment, cure rates differed between groups: 88.0% (88/100 assessable) for BCDT versus 100.0% (100/100 assessable) for CC (P < 0.001). The 12 initially unsuccessful BCDT cases (all Kikiros grade 2 at 4 weeks) continued with home stretching exercises; 10 achieved cure by 6 months, while 2 (2.0%) required conversion to circumcision because of inadequate response. All 4-week assessments were complete in the patients evaluated; the missing 4 of the original 200 (2.0%) were absent at the 4-week visit but reappeared at 6 months. Table 2Treatment Outcomes, Safety Profile, and Effect Size QuantificationOutcomeBCDT (n = 100)CC (n = 100)P-valueEffect Size*PRIMARY EFFICACY Cure at 4 weeks, n (%)88 (88.0)100 (100)< 0.001ARD = 12.0% Cure at 6 months, n (%)98 (98.0)100 (100)0.497ARD = 2.0%PROCEDURAL OUTCOMES Operative time, min, mean ± SD5.03 ± 0.6229.38 ± 6.69< 0.001d=-5.13 Healing time, days, mean ± SD6.74 ± 2.1315.90 ± 3.06< 0.001d=-3.47PAIN-RELATED OUTCOMES Pain occurrence, n (%)65 (65.0)99 (99.0)< 0.001NNT = 3 Pain duration, hours, mean ± SD†21.2 ± 14.093.2 ± 55.6< 0.001d=-1.63 FLACC score at 24 h, mean ± SD2.59 ± 1.445.22 ± 2.07< 0.001d=-1.48 FLACC < 4, n (%)78 (78.0)23 (23.0)< 0.001NNT = 2EDEMA OUTCOMES Edema occurrence, n (%)60 (60.0)100 (100)< 0.001NNT = 2.5 Edema duration, hours, mean ± SD†21.1 ± 14.781.3 ± 59.1< 0.001d=-1.26OTHER COMPLICATIONS Bleeding, n (%)0 (0)2 (2.0)0.497- Dysuria, n (%)2 (2.0)7 (7.0)0.170- Local infection, n (%)0 (0)2 (2.0)0.497- Wound dehiscence, n (%)N/A2 (2.0)--Abbreviations: FLACC Face, Legs, Activity, Cry, Consolability scale, N/A Not applicable*Effect size: d=Cohen’s d; ARD=absolute risk difference; NNT=number needed to treat (for benefit)†Among patients experiencing the complication Treatment Outcomes, Safety Profile, and Effect Size Quantification Abbreviations: FLACC Face, Legs, Activity, Cry, Consolability scale, N/A Not applicable *Effect size: d=Cohen’s d; ARD=absolute risk difference; NNT=number needed to treat (for benefit) †Among patients experiencing the complication At the primary endpoint of 6 months, cure rates converged: BCDT 98.0% (90/92 assessable) versus CC 100.0% (92/92 assessable). The absolute risk difference (BCDT minus CC) was − 2.0% (95% CI − 4.7% to + 0.7%). Because the lower bound of the 95% CI (− 4.7%) lay above the pre-specified non-inferiority margin of − 10%, BCDT was declared non-inferior to CC for 6-month anatomical cure (P = 0.497 for superiority test, retained for completeness). The Kikiros-grade trajectory in the BCDT group demonstrated progressive improvement: median grade decreased from 4 (baseline) to 2 (4 weeks) to 0 (6 months), indicating sustained short-term anatomical restoration (Fig. 1A). Procedural outcomes BCDT demonstrated substantial procedural efficiency advantages (Table 2). Mean operative time was 5.03 ± 0.62 min for BCDT compared with 29.38 ± 6.69 min for CC—a 5.8-fold reduction (P < 0.001; Cohen’s d=-5.13, indicating an extremely large effect). All BCDT procedures were completed under topical anesthesia (100%), whereas CC required general anesthesia in 70% and caudal block in 30% of cases. Time to complete healing was significantly shorter in the BCDT group: 6.74 ± 2.13 days versus 15.90 ± 3.06 days (P < 0.001; Cohen’s d=-3.47; Fig. 1B). This 9.2-day difference (2.4-fold reduction) translates to substantially earlier return to normal activities, reduced caregiver burden, and decreased healthcare resource utilization. Safety outcomes and complication profile Complication profiles differed substantially between groups across all assessed parameters (Table 2; Fig. 2). The most clinically significant findings related to pain-associated outcomes: Safety profile and family-centered outcomes. A Forest plot displaying odds ratios (95% CI) for complications comparing BCDT versus CC. Diamond markers indicate point estimates; horizontal lines represent 95% confidence intervals. Values < 1 favor BCDT. The dashed vertical line represents the null effect (OR = 1). B Parent satisfaction distribution by treatment group showing proportion at each satisfaction level (1–5 scale). C Correlation between parent health literacy (NVS score) and 4-week home care compliance, stratified by treatment group. Trend lines with 95% confidence bands are displayed. Pearson correlation coefficient and P-value are indicated. D Propensity score distributions before matching confirming adequate overlap between groups. BCDT, balloon catheter dilation treatment; CC, conventional circumcision; NVS, Newest Vital Sign Pain occurrence was markedly lower in the BCDT group: 65.0% versus 99.0% (P < 0.001; absolute risk reduction = 34.0%; NNT = 3). Among patients experiencing pain, duration was substantially shorter: 21.2 ± 14.0 h (BCDT) versus 93.2 ± 55.6 h (CC) (P < 0.001; Cohen’s d=-1.63). The FLACC pain score at 24 h—a validated pediatric pain measure—demonstrated clinically meaningful superiority for BCDT: 2.59 ± 1.44 versus 5.22 ± 2.07 (P < 0.001; Cohen’s d=-1.48). Notably, 78% of BCDT patients had FLACC scores < 4 (indicating minimal/no significant pain) compared with only 23% in the CC group. Edema, a universal finding following CC, occurred in 100% of circumcised patients compared with 60.0% following BCDT (P < 0.001; absolute risk reduction = 40.0%; NNT = 2.5). Duration among affected patients was significantly shorter in the BCDT group: 21.1 ± 14.7 versus 81.3 ± 59.1 h (P < 0.001; Cohen’s d=-1.26). Other complications, while infrequent in both groups, showed trends favoring BCDT: bleeding requiring intervention (0% vs. 2.0%), dysuria (2.0% vs. 7.0%), local infection (0% vs. 2.0%), and wound dehiscence (not applicable vs. 2.0%). No cases of incarceration, paraphimosis, or serious adverse events requiring hospitalization occurred in either group, confirming the overall safety of both approaches when performed by experienced surgeons. Patient-reported and family-centered outcomes Parent satisfaction demonstrated high levels in both groups, with trends favoring BCDT (Table 3). The proportion rating their experience as ‘very satisfied’ (score 5) was 96.0% for BCDT versus 88.0% for CC (P = 0.068). Mean satisfaction scores were 4.93 ± 0.36 (BCDT) versus 4.80 ± 0.62 (CC) (P = 0.040; Cohen’s d = 0.26). Net Promoter Scores, reflecting recommendation likelihood, were comparable: 9.52 ± 0.92 versus 9.30 ± 1.51 (P = 0.215), with 91% (BCDT) and 85% (CC) classified as ‘promoters’ (score ≥ 9). Table 3Patient-Reported Outcomes and Family-Centered MeasuresMeasureBCDT (n = 100)CC (n = 100)P-valuePARENT SATISFACTIONOverall score (1–5), mean ± SD4.93 ± 0.364.80 ± 0.620.040Very satisfied (score = 5), n (%)96 (96.0)88 (88.0)0.068NPS score (0–10), mean ± SD9.52 ± 0.929.30 ± 1.510.215NPS Promoters (score ≥ 9), n (%)91 (91.0)85 (85.0)0.248QUALITY OF LIFE (PedsQL)Baseline score, mean ± SD78.85 ± 10.3176.98 ± 11.740.2326-month score, mean ± SD86.36 ± 9.6484.32 ± 11.470.175Change from baseline, mean ± SD7.51 ± 4.827.34 ± 5.210.812PARENT ANXIETY (STAI)Baseline score, mean ± SD41.12 ± 11.8942.39 ± 11.980.4536-month score, mean ± SD35.21 ± 9.5435.78 ± 10.210.681HOME CARE COMPLIANCE (0–4)2-week score, mean ± SD3.42 ± 0.683.28 ± 0.820.1864-week score, mean ± SD3.08 ± 0.752.95 ± 0.880.259Abbreviations: NPS Net Promoter Score, PedsQL Pediatric Quality of Life Inventory 4.0, STAI State-Trait Anxiety Inventory Patient-Reported Outcomes and Family-Centered Measures Abbreviations: NPS Net Promoter Score, PedsQL Pediatric Quality of Life Inventory 4.0, STAI State-Trait Anxiety Inventory Quality of life, measured by PedsQL 4.0, improved in both groups at 6 months. Mean scores increased from 78.85 ± 10.31 to 86.36 ± 9.64 (BCDT; Δ = 7.51 points) and from 76.98 ± 11.74 to 84.32 ± 11.47 (CC; Δ = 7.34 points), with no significant between-group difference in magnitude of improvement (P = 0.175). Both improvements exceeded the established minimal clinically important difference of 4.4 points for the PedsQL [24]. Parent anxiety, assessed by STAI, decreased significantly in both groups: from 41.12 ± 11.89 to 35.21 ± 9.54 (BCDT) and from 42.39 ± 11.98 to 35.78 ± 10.21 (CC), with comparable reduction magnitudes between groups (P = 0.68 for interaction). This consistent anxiety reduction suggests that successful treatment resolution—regardless of modality—alleviates the psychological burden on caregivers. Health literacy and compliance analysis A key novel finding of this study concerns the relationship between parent health literacy and post-treatment compliance. NVS health literacy scores demonstrated a significant positive correlation with 4-week compliance scores (r = 0.42; P < 0.001; Fig. 2C). Parents with adequate health literacy (NVS ≥ 4) achieved significantly higher compliance scores compared with those with limited literacy: 3.21 ± 0.58 versus 2.74 ± 0.71 (P < 0.001; Cohen’s d = 0.73). This association was particularly relevant for the BCDT group, where home stretching exercises constitute an essential component of post-procedure care. Subgroup analysis revealed that among BCDT patients with adequate health literacy (n = 68), the 4-week cure rate was 94.1% compared with 78.1% among those with limited literacy (n = 32) (P = 0.028), suggesting that health literacy-informed patient selection may optimize BCDT outcomes. Discussion This retrospective study of 200 paediatric patients with symptomatic / pathological phimosis provides comparative evidence that, in this selected population, balloon catheter dilation treatment offers short-term (6-month) anatomical efficacy non-inferior to conventional circumcision, together with advantages in procedural efficiency, pain, recovery, and parent satisfaction. We deliberately frame these findings as short-term outcomes: the 6-month window captures the primary anatomical endpoint and the acute safety/experience profile, but is insufficient to establish durable cure, long-term re-stenosis rates, or post-pubertal preputial function. The findings should also not be interpreted as a recommendation to intervene on asymptomatic physiological phimosis, the majority of which resolves spontaneously by puberty. Efficacy outcomes in context of current evidence Our short-term 6-month BCDT cure rate of 98% is consistent with the range reported in early single-centre Chinese paediatric BCDT series, including the foundational 512-case report by He and Zhou (1991) [9]. The 2% absolute difference from CC (which achieved 100% anatomical success by definition of complete foreskin removal) fell well within our pre-specified non-inferiority margin of 10%, and the 95% confidence interval (− 4.7% to + 0.7%) confirmed statistical non-inferiority. We note, however, that contemporary multicentre comparative data using validated outcome instruments and direct head-to-head comparison against circumcision remain sparse in the peer-reviewed international literature; the present single-centre cohort therefore adds short-term comparative evidence rather than confirming a pre-existing high-quality international benchmark. Importantly, the two BCDT treatment failures in our cohort (2%) successfully underwent subsequent circumcision without additional complications, demonstrating that BCDT does not compromise the option for definitive surgical management when conservative treatment proves insufficient. This sequential approach—BCDT as first-line with circumcision reserved for failures—aligns with the EAU 2024–2025 guidelines emphasizing conservative management before surgical intervention [1]. Clinical significance of safety advantages The safety profile differences between BCDT and CC demonstrated in this study are not merely statistically significant but clinically meaningful, as evidenced by large effect sizes and practically relevant NNT values. The pain-related findings are particularly noteworthy: the 34% absolute reduction in pain occurrence (NNT = 3), 72-hour reduction in pain duration, and 2.6-point difference in FLACC scores represent substantial improvements in the pediatric patient experience. The Cohen’s d values for procedure time (-5.13), healing time (-3.47), and FLACC scores (-1.48) far exceed conventional thresholds for ‘large’ effects (d ≥ 0.8), indicating that these differences would be readily apparent in clinical practice rather than requiring large sample sizes for detection. For families weighing treatment options, these effect magnitudes translate to tangible differences: a 5-minute office procedure versus a 30-minute operation requiring general anesthesia; one week versus over two weeks of healing; and minimal versus significant post-procedural pain. Our complication rates for CC (bleeding 2%, infection 2%, wound dehiscence 2%) are consistent with recent meta-analytic estimates. The 2021 Shabanzadeh meta-analysis reported 3.84% overall complications across 4 million circumcisions, with therapeutic circumcisions at 7.47%0.5 The 2024 systematic review by Yao et al. similarly confirmed that while circumcision is generally safe, it carries inherent surgical risks that may be avoided with minimally invasive alternatives [8]. A 2025 five-year retrospective analysis from a teaching hospital in Ghana further documented a persistent burden of paediatric circumcision complications across resource-varied healthcare settings, reinforcing the rationale for foreskin-preserving alternatives where clinically appropriate [25]. Novel contribution: health literacy and treatment adherence A key novel contribution of this study is the systematic evaluation of parent health literacy as a determinant of post-treatment outcomes. The significant correlation between NVS scores and home care compliance (r = 0.42) has important clinical implications. BCDT’s efficacy depends partly on sustained home stretching exercises to maintain the dilated preputial orifice; inadequate compliance may permit re-stenosis. Our finding that BCDT patients with adequate health literacy achieved significantly higher 4-week cure rates (94% vs. 78%) suggests that health literacy assessment could inform shared decision-making regarding treatment selection. For families with limited health literacy, enhanced educational interventions — including visual aids, teach-back methods, and more frequent follow-up — may be warranted to optimize BCDT outcomes. Alternatively, circumcision (which requires less ongoing home management) might be preferentially considered when compliance concerns are significant. This personalized approach to treatment selection, informed by family-centered factors beyond disease characteristics alone, represents an advancement toward precision medicine in pediatric urology [26]. Alignment with international guidelines and quality improvement initiatives Our findings have important implications for clinical practice guidelines and quality improvement. The 2025 analysis by Fuentes et al. documented that 47% of phimosis surgeries in their Spanish cohort involved asymptomatic physiological phimosis—suggesting substantial overutilization of circumcision contrary to current European recommendations [2]. BCDT offers a bridge between purely conservative management (topical steroids, watchful waiting) and definitive surgical intervention, potentially reducing unnecessary circumcisions while providing effective treatment for symptomatic patients. From a healthcare systems perspective, the procedural efficiency of BCDT offers resource utilization benefits: elimination of general anesthesia requirements, reduced operative time enabling higher throughput, and decreased post-procedural complications reducing follow-up burden. These factors, combined with preserved patient option for future circumcision if needed, support BCDT integration into staged management algorithms for pediatric phimosis [27]. Analogous device-based foreskin-preserving approaches have also been reviewed in the adult phimosis literature, where multiple non-excisional options now coexist alongside standard surgical treatments and offer relevant cross-population context for paediatric practice [28]. Limitations and methodological considerations Several limitations warrant consideration when interpreting our findings. First, the retrospective design introduces potential selection bias; patients receiving BCDT versus CC may have differed in unmeasured characteristics influencing treatment allocation. However, propensity score analysis confirmed baseline balance on measured covariates, mitigating this concern. Second, the single-center design may limit generalizability; multicenter replication across diverse healthcare settings and populations is warranted. Third, follow-up was limited to 6 months. While this captures the primary outcome of anatomical cure and the acute safety profile, it does not establish durable cure, long-term recurrence rates (particularly for BCDT, where re-stenosis might occur if stretching adherence wanes), or post-pubertal anatomical and psychosexual outcomes. The most clinically meaningful endpoint — persistent retractability after puberty — therefore remains unaddressed by these data. Fourth, our study excluded BXO, which represents a distinct entity with different treatment considerations [15]; our findings should not be extrapolated to that population. Fifth, no patient in either group received a structured trial of topical corticosteroid therapy before intervention; current European guidelines recommend topical corticosteroids as first-line therapy for symptomatic paediatric phimosis [1, 3], so the absence of a steroid-pretreated arm is an important limitation that may have biased the indication mix toward earlier procedural management than current best practice would now support. Sixth, despite our use of indication-based inclusion criteria, some risk remains that mild or borderline-physiological cases may have been included; this raises the possibility that a subset of these procedures represented overtreatment of disease that would have resolved spontaneously. The 2025 analysis by Fuentes et al. flagged exactly this concern at a European level, with 47% of phimosis surgeries in their cohort involving asymptomatic physiological cases [2]. This caution is reinforced by canonical primary-care guidance emphasising that most paediatric phimosis referrals represent physiologically phimotic foreskins that do not warrant intervention and that the distinction between physiological and pathological phimosis must be made before any procedural option is offered [29]. Seventh, surgeon experience may influence outcomes; all BCDT procedures in our cohort were performed by surgeons with ≥ 3 years of experience in the technique, so learning-curve effects should be considered when implementing BCDT at new centres. Eighth, formal economic evaluation incorporating direct costs (procedure, anaesthesia, follow-up) and indirect costs (caregiver time, school absence) was beyond our scope and is needed before broad health-system adoption can be recommended. Future research directions This study generates several hypotheses warranting prospective investigation. Randomized controlled trials comparing BCDT, topical corticosteroids, and circumcision would definitively establish the evidence hierarchy for pediatric phimosis management. Development and validation of phimosis-specific patient-reported outcome measures, incorporating both child and parent perspectives, would enhance assessment beyond anatomical endpoints [30]. Investigation of predictive factors for BCDT success — including phimosis severity, patient age, compliance capacity, and tissue characteristics — could enable personalized treatment selection algorithms. Conclusions This retrospective comparative study of 200 paediatric patients with symptomatic phimosis demonstrates that, over a 6-month follow-up window, balloon catheter dilation treatment achieves anatomical cure rates non-inferior to conventional circumcision (98.0% vs. 100.0%) while offering clinically meaningful short-term advantages across multiple outcome domains. BCDT provides a 6-fold reduction in procedure time, a 34% absolute reduction in pain incidence, 2.4-fold faster healing, and consistently high parent satisfaction—all with effect sizes indicating substantial practical significance within this time horizon. As a foreskin-preserving, minimally invasive option requiring only topical anaesthesia, BCDT may be considered for carefully selected children with symptomatic / pathological phimosis, after appropriate counselling and within a stepwise conservative management strategy in which watchful waiting and topical corticosteroids remain first-line therapy in line with current European guidelines. Our data do not support BCDT (or circumcision) for asymptomatic physiological phimosis, which typically resolves spontaneously by puberty. Treatment selection should be individualised through shared decision-making with families, taking into account symptom burden, response to prior conservative therapy, and parent health literacy for post-procedure home-care adherence. Prospectively designed, multicentre studies with post-pubertal follow-up — and ideally direct head-to-head comparison against topical corticosteroid therapy — are needed before broader first-line adoption of BCDT can be recommended. Authors’ contributions (I) Conception and design: Nan Jin; (II) Administrative support: Nan Jin; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: Xia Zhao, Li Zhang; (V) Data analysis and interpretation: Xia Zhao; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors. Funding This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors. Data availability The data that support the findings of this study are available from the corresponding author upon reasonable request. Declarations Ethics approval and consent to participate This study was approved by the Institutional Review Board of Chinese PLA General Hospital (Approval No. KGR-2025486) and conducted in accordance with the Declaration of Helsinki. Given the retrospective design utilizing de-identified medical records, the requirement for individual informed consent was waived. Consent for publication Not applicable. Competing interests The authors declare no competing interests. Footnotes Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. References Associated Data Data Availability Statement The data that support the findings of this study are available from the corresponding author upon reasonable request.